Sana Biotechnology SANA Contingent Consideration Liability (Non-Current)
Contingent Consideration Liability (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent.
The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sana Biotechnology's contingent consideration liability (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sana Biotechnology's contingent consideration liability (non-current)?
- Sana Biotechnology (SANA) reported contingent consideration liability (non-current) of $80.91M in Q1 2026.
- How has Sana Biotechnology's contingent consideration liability (non-current) changed year-over-year?
- Sana Biotechnology's contingent consideration liability (non-current) decreased by 27.0% year-over-year, from $110.83M to $80.91M.
- What is the long-term trend for Sana Biotechnology's contingent consideration liability (non-current)?
- Over 5 years (2020 to 2025), Sana Biotechnology's contingent consideration liability (non-current) has grown at a -7.3% compound annual growth rate (CAGR), from $121.9M to $83.52M.
- What does contingent consideration liability (non-current) mean?
- This represents the long-term portion of estimated future payments owed to sellers following a business acquisition, contingent upon the achievement of specific performance milestones or financial targets. It reflects the present value of obligations expected to be settled beyond the next twelve months. Investors monitor this to assess the potential long-term financial impact of past M&A activity and the likelihood of future cash outflows related to integration success.